[{"id":"1a0f9386-4e8b-4cdd-9e39-8af1012d0af9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215548","created_at":"2022-02-05T18:27:48.529Z","updated_at":"2025-02-25T14:08:36.534Z","phase":"Phase 2","brief_title":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","source_id_and_acronym":"NCT05215548","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"8edf0eb7-d0e0-49b2-b787-cd7e18808b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02597946","created_at":"2021-01-18T12:36:41.049Z","updated_at":"2025-02-25T14:00:49.865Z","phase":"Phase 2","brief_title":"Afatinib in NSCLC With HER2 Mutation","source_id_and_acronym":"NCT02597946","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • KIT","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2 • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 07/22/2018","primary_completion_date":" 07/22/2018","study_txt":" Completion: 07/22/2018","study_completion_date":" 07/22/2018","last_update_posted":"2025-02-19"},{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"a00222c5-3654-4b1c-8e1f-3f6063d2350d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03083678","created_at":"2021-01-18T15:11:26.156Z","updated_at":"2025-02-25T15:10:32.768Z","phase":"Phase 2","brief_title":"Afatinib in Locally Advanced and Metastatic Chordoma","source_id_and_acronym":"NCT03083678","lead_sponsor":"Leiden University Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-13"},{"id":"830f0798-1d87-4b27-be23-d2bdac97c17f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01649271","created_at":"2021-01-18T07:06:15.291Z","updated_at":"2025-02-25T15:25:12.158Z","phase":"Phase 1","brief_title":"Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.","source_id_and_acronym":"NCT01649271","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/23/2012","start_date":" 07/23/2012","primary_txt":" Primary completion: 06/23/2016","primary_completion_date":" 06/23/2016","study_txt":" Completion: 06/23/2016","study_completion_date":" 06/23/2016","last_update_posted":"2025-02-11"},{"id":"0061b93e-583a-42c0-8bd3-4e877410955f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00950742","created_at":"2021-01-18T03:41:51.942Z","updated_at":"2025-02-25T15:25:03.808Z","phase":"Phase 1","brief_title":"Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.","source_id_and_acronym":"NCT00950742","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"021a5f18-f5e7-498d-a188-e4903f2c76f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588609","created_at":"2022-10-20T14:11:50.019Z","updated_at":"2025-02-25T16:54:29.545Z","phase":"Phase 2","brief_title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","source_id_and_acronym":"NCT05588609","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-04"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"6f4faf68-b16d-468b-9596-4d2ec114a446","acronym":"","url":"https://clinicaltrials.gov/study/NCT02364609","created_at":"2021-01-18T11:15:31.840Z","updated_at":"2025-02-25T16:14:29.149Z","phase":"Phase 1","brief_title":"Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib","source_id_and_acronym":"NCT02364609","lead_sponsor":"Jonathan Riess","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • erlotinib • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2024-10-16"},{"id":"8c54ec0b-d0c1-4fe6-a519-4d78f4e6dc25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04909073","created_at":"2021-06-01T17:53:35.882Z","updated_at":"2024-07-02T16:35:02.774Z","phase":"","brief_title":"Observational Study of Afatinib 30 mg Daily","source_id_and_acronym":"NCT04909073","lead_sponsor":"National University Hospital, Singapore","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-17"},{"id":"9c382546-d526-411a-9404-d92947184867","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085755","created_at":"2023-10-17T15:12:33.857Z","updated_at":"2024-07-02T16:35:03.809Z","phase":"Phase 1/2","brief_title":"Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer","source_id_and_acronym":"NCT06085755","lead_sponsor":"Jeeyun Lee","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-14"},{"id":"5cbd364b-f758-45a6-86eb-66a9228fce4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06302621","created_at":"2024-03-13T01:30:21.478Z","updated_at":"2024-07-02T16:35:07.278Z","phase":"Phase 1","brief_title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT06302621","lead_sponsor":"Massachusetts General Hospital","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-26"},{"id":"c5cabfd9-b1fc-42b8-8fab-a1e3bddb7d32","acronym":"KRYSTAL-1","url":"https://clinicaltrials.gov/study/NCT03785249","created_at":"2021-01-17T17:34:47.900Z","updated_at":"2024-07-02T16:35:10.063Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","source_id_and_acronym":"NCT03785249 - KRYSTAL-1","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Gilotrif (afatinib) • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 822","initiation":"Initiation: 12/26/2018","start_date":" 12/26/2018","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-04-11"},{"id":"bea341dc-ce91-43e5-9281-085d350a6e88","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439136","created_at":"2021-01-18T21:22:05.787Z","updated_at":"2024-07-02T16:35:11.236Z","phase":"Phase 2","brief_title":"Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)","source_id_and_acronym":"NCT04439136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 01/22/2021","primary_completion_date":" 01/22/2021","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-04-05"},{"id":"0271e51f-f1cb-4fb7-8adf-071968b48ba1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01853826","created_at":"2021-01-17T17:10:45.936Z","updated_at":"2024-07-02T16:35:12.724Z","phase":"Phase 3","brief_title":"An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","source_id_and_acronym":"NCT01853826","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 481","initiation":"Initiation: 07/17/2013","start_date":" 07/17/2013","primary_txt":" Primary completion: 04/30/2018","primary_completion_date":" 04/30/2018","study_txt":" Completion: 03/06/2024","study_completion_date":" 03/06/2024","last_update_posted":"2024-03-26"},{"id":"4a4ee7a4-f838-4eeb-b772-111cfaff0da0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02438722","created_at":"2024-02-04T02:18:10.349Z","updated_at":"2024-07-02T16:35:19.933Z","phase":"Phase 2/3","brief_title":"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02438722","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Gilotrif (afatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 05/07/2015","start_date":" 05/07/2015","primary_txt":" Primary completion: 09/25/2018","primary_completion_date":" 09/25/2018","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-02-09"},{"id":"834da53e-fc93-4ae2-8e81-d4ca0ac61e29","acronym":"START","url":"https://clinicaltrials.gov/study/NCT04206787","created_at":"2021-01-18T20:29:27.240Z","updated_at":"2024-07-02T16:35:22.019Z","phase":"","brief_title":"The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer","source_id_and_acronym":"NCT04206787 - START","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 12/18/2023","primary_completion_date":" 12/18/2023","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-01-26"},{"id":"74b38b12-7060-4bc1-ac90-62695355c469","acronym":"DARWIN1","url":"https://clinicaltrials.gov/study/NCT02183883","created_at":"2021-01-18T10:11:22.340Z","updated_at":"2024-07-02T16:35:27.699Z","phase":"Phase 2","brief_title":"Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity","source_id_and_acronym":"NCT02183883 - DARWIN1","lead_sponsor":"University College, London","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/16/2016","start_date":" 12/16/2016","primary_txt":" Primary completion: 03/22/2023","primary_completion_date":" 03/22/2023","study_txt":" Completion: 03/22/2023","study_completion_date":" 03/22/2023","last_update_posted":"2023-11-29"},{"id":"c4b83354-ad5b-4b99-8a70-e0986de8f71e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522768","created_at":"2021-01-18T06:24:39.292Z","updated_at":"2024-07-02T16:35:30.714Z","phase":"Phase 2","brief_title":"Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer","source_id_and_acronym":"NCT01522768","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Gilotrif (afatinib) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 02/20/2023","study_completion_date":" 02/20/2023","last_update_posted":"2023-11-01"},{"id":"9cf49ba9-0ebf-4ee7-81f0-69060dfd38a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04795245","created_at":"2021-03-23T07:14:19.991Z","updated_at":"2024-07-02T16:35:31.118Z","phase":"","brief_title":"Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma","source_id_and_acronym":"NCT04795245","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 857","initiation":"Initiation: 08/26/2021","start_date":" 08/26/2021","primary_txt":" Primary completion: 10/16/2023","primary_completion_date":" 10/16/2023","study_txt":" Completion: 10/16/2023","study_completion_date":" 10/16/2023","last_update_posted":"2023-10-31"},{"id":"423ab1f8-040e-4b8f-bcaf-c93050ec30b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02491099","created_at":"2021-01-18T12:00:29.863Z","updated_at":"2024-07-02T16:35:31.668Z","phase":"Phase 2","brief_title":"A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma","source_id_and_acronym":"NCT02491099","lead_sponsor":"Yale University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-10-26"},{"id":"6ad66673-5cbc-48f3-9362-fb712170e656","acronym":"AFACET","url":"https://clinicaltrials.gov/study/NCT03727724","created_at":"2021-01-18T18:15:54.614Z","updated_at":"2025-02-25T16:08:33.372Z","phase":"Phase 2","brief_title":"Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer","source_id_and_acronym":"NCT03727724 - AFACET","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/04/2018","start_date":" 12/04/2018","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2023-10-18"},{"id":"2bafa7f6-34b1-49c6-949e-a3fe4e4c7ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06071013","created_at":"2023-10-06T14:11:38.244Z","updated_at":"2024-07-02T16:35:34.351Z","phase":"Phase 2","brief_title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","source_id_and_acronym":"NCT06071013","lead_sponsor":"China Medical University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Gilotrif (afatinib) • gefitinib • nintedanib"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 08/27/2026","primary_completion_date":" 08/27/2026","study_txt":" Completion: 08/27/2026","study_completion_date":" 08/27/2026","last_update_posted":"2023-10-06"}]